ストックスクリーナーアプリを入手
0.8457
9.36%
-0.0873
アフターアワーズ：
.88
0.0343
+4.06%
前日終値:
$0.933
開ける：
$0.9101
24時間の取引高:
839.59K
Relative Volume:
1.18
時価総額：
$112.22M
収益：
$140.46M
当期純損益:
$-146.34M
株価収益率:
-0.6407
EPS:
-1.32
ネットキャッシュフロー:
$-117.73M
1週間 パフォーマンス:
-0.21%
1か月 パフォーマンス:
-4.70%
6か月 パフォーマンス:
-25.16%
1年 パフォーマンス:
-4.98%
1日の値動き範囲:
$0.8457
$0.9324
1週間の範囲:
$0.8402
$1.13
52週間の値動き範囲:
$0.6174
$1.95
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
名前
Karyopharm Therapeutics Inc
セクター
電話
617-658-0600
住所
85 WELLS AVENUE, NEWTON, MA
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-01-19 | 開始されました | Piper Sandler | Overweight |
| 2022-11-04 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-11-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-08-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-08-06 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | 開始されました | Morgan Stanley | Overweight |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-17 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-07-23 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-07-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-05 | 繰り返されました | Robert W. Baird | Outperform |
| 2019-03-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-02-28 | 繰り返されました | BofA/Merrill | Underperform |
| 2019-02-27 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | 開始されました | B. Riley FBR | Buy |
| 2018-11-09 | アップグレード | Wedbush | Neutral → Outperform |
| 2018-05-24 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-04-02 | 再開されました | Leerink Partners | Outperform |
| 2017-11-15 | 再開されました | H.C. Wainwright | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2016-09-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-30 | アップグレード | Jefferies | Hold → Buy |
| 2016-08-18 | 開始されました | H.C. Wainwright | Buy |
| 2016-06-28 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Karyopharm Therapeutics Inc (KPTI) 最新ニュース
Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript - Yahoo Finance
Karyopharm Therapeutics: Q3 Earnings Snapshot - San Francisco Chronicle
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings: EPS Loss of - GuruFocus.com
Karyopharm Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress - PR Newswire
Karyopharm Therapeutics' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com UK
Karyopharm Therapeutics Inc (KPTI) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
KPTIKaryopharm Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - MSN
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Karyopharm Therapeutics (KPTI) to Release Quarterly Earnings on Tuesday - MarketBeat
Karyopharm Therapeutics' (KPTI) Buy Rating Reiterated at HC Wainwright - MarketBeat
Karyopharm updates SENTRY trial endpoints, eyes 2025 data - Investing.com India
Karyopharm updates SENTRY trial endpoints, eyes 2025 data By Investing.com - Investing.com Canada
Karyopharm gains after changes to late-stage trial - MSN
Karyopharm stock gains as late-stage trial changes (KPTI:NASDAQ) - Seeking Alpha
Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024 - StockTitan
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis - StockTitan
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024 - Investor Relations | Karyopharm Therapeutics
Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
Highbridge Capital Management's Strategic Acquisition of Karyopharm Therapeutics Shares - Yahoo Finance
Highbridge Capital Management's Strategic Acquisition of Karyoph - GuruFocus.com
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Above 50-Day Moving AverageShould You Sell? - MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Holdings Lifted by AQR Capital Management LLC - MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Karyopharm Therapeutics Inc [KPTI] Records 200-Day SMA of $1.0212 - Knox Daily
Ratios in Focus: Analyzing Karyopharm Therapeutics Inc (KPTI)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
KPTI’s latest rating updates from top analysts. - Knox Daily
Karyopharm Therapeutics Inc (KPTI) is looking forward to a strong quarter - SETE News
Karyopharm Therapeutics Inc (KPTI) stock analysis: A simple moving average approach - US Post News
Cubist Systematic Strategies LLC Buys New Shares in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Marshall Wace LLP Decreases Position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Cubist Systematic Strategies LLC Takes Position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - MarketBeat
Karyopharm Therapeutics Inc [NASDAQ: KPTI] Sees Decrease in Stock Value - Knox Daily
Was Karyopharm Therapeutics Inc (KPTI)’s session last reading good? - US Post News
Monitoring Karyopharm Therapeutics Inc (KPTI) after recent insider movements - Knox Daily
Analyzing the Impact of Earnings Reports on Karyopharm Therapeutics Inc Inc. (KPTI) Price Performance - The InvestChronicle
Why Investors Shouldn't Be Surprised By Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Low P/S - Simply Wall St
Financial Snapshot: Analyzing Karyopharm Therapeutics Inc (KPTI)’s Key Ratio Metrics - The Dwinnex
A new trading data show Karyopharm Therapeutics Inc (KPTI) is showing positive returns. - SETE News
Karyopharm Therapeutics' SWOT analysis: pipeline potential drives stock outlook - Investing.com India
Karyopharm Therapeutics' SWOT analysis: pipeline potential drives stock outlook By Investing.com - Investing.com UK
SVP, General Counsel&Secretary Mano Michael sold 3,971 shares of Karyopharm Therapeutics Inc [KPTI] - Knox Daily
Karyopharm Therapeutics Inc (KPTI) Performance and Fundamentals Dashboard tells a completely different story - SETE News
The Globe and Mail - The Globe and Mail
A stock that deserves closer examination: Karyopharm Therapeutics Inc (KPTI) - US Post News
Metric Deep Dive: Understanding Karyopharm Therapeutics Inc (KPTI) Through its Ratios - The Dwinnex
KJTS Group shares climb to near six-week high after contract win - The Edge Malaysia
Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements - Barchart
KEC International Shares Surge 3% on Securing Orders Worth Rs 1,003 Crore - EquityPandit
Karyopharm Therapeutics Inc (KPTI) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):